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Desmopressin is an Effective Treatment for Mixed Nocturia with
Nocturnal Polyuria and Decreased Nocturnal Bladder Capacity
To investigate the efficacy and safety of desmopressin in patients with mixed nocturia,  
Patients aged ≥18 yr with mixed nocturia (≥2 voids/night and a nocturnal polyuria index 
[NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The 
optimum dose of oral desmopressin was determined during a 3-week dose-titration period 
and the determined dose was maintained for 4 weeks. The efficacy was assessed by the 
frequency-volume charts and the sleep questionnaire. The primary endpoint was the 
proportion of patients with a 50% or greater reduction in the number of nocturnal voids 
(NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) 
were included in the analysis. The proportion of patients with a 50% or greater reduction 
in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and 
the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. 
The mean duration of sleep until the first NV was prolonged from 118.4±44.1 to 
220.3±90.7 min (P<0.001). The overall impression of patients about their quality of sleep 
improved. Adverse events occurred in 6 patients, including one asymptomatic 
hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed 
nocturia.
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INTRODUCTION
Nocturia is defined as waking one or more times to void during 
the period between going to bed with the intention of sleeping 
and waking with the intention of arising (1, 2). Recent multina-
tional population-based, cross-sectional survey (EPIC) of adults 
aged ≥18 yr using 2002 International Continence Society (ICS) 
definitions showed overall prevalence of any lower urinary tract 
symptoms (LUTS) was 62.5% in men and 66.6% in women and 
nocturia (≥2 times/night) was the most commonly reported 
storage symptom for both men (20.9%) and women (24.0%) (3). 
Similarly, the epidemiological data in adult Korean aged 40-89 
yr national community showed that of 2005 subjects interviewed, 
33.5% reported voiding once per night and 48.2% twice or more 
per night and in addition, the impact of nocturia on daily life 
was reported by 14.6% of subjects (4). Nocturia is associated 
with sleep disruption and consequently impairs the quality of 
life (QOL) and potentially increases mortality (5, 6). 
  Although this condition should be evaluated and treated, it 
has only recently been recognized as a clinical entity in its own 
right, rather than just one of the features of LUTS. Relatively few 
patients with nocturia seek medical care because of a lack of 
awareness or misconceptions about nocturia. Furthermore, 
there is a general lack of knowledge about treatment options for 
nocturia (4, 7, 8). Because the pathophysiology of nocturia is 
multifactorial and complex, it is important to adopt a systemat-
ic approach to identify the possible causal factors of nocturia 
and to treat them accordingly. Patients with nocturia can be 
categorized as having one of the following three disorders: (1) 
nocturnal polyuria (NP) in which the voided urine volume dur-
ing the hours of sleep exceeds 33% of the 24-hr output (2), de-
creased nocturnal bladder capacity (NBC), which results in a 
nocturnal urinary volume greater than the maximum voided 
volume (MVV), (3) or mixed nocturia, a combination of the pre-Lee HW, et al.  •  Desmopressin in Mixed Nocturia
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ceding two categories (9, 10). In one retrospective study of 194 
patients with nocturia, 13 (7%) had pure NP, 111 (57%) had dimin-
ished NBC, and 70 (36%) had a combination of the two (9, 11).
  Desmopressin is a synthetic analogue of arginine vasopres-
sin (AVP), but desmopressin has a more potent antidiuretic ef-
fect than AVP. Desmopressin has been shown to be an effective 
treatment for nocturia with NP by decreasing night-time urine 
production (12-16). However, a patient with a significantly de-
creased nocturnal bladder capacity index (NBCi) >2 may have 
bladder outlet obstruction, detrusor overactivity (DO), sensory 
urgency, and/or primary bladder disorders such as infection, 
or malignancy (16). Specific treatment of the underlying urolog-
ical condition would therefore be expected to have a mitigating 
effect on decreased NBC as a component of nocturia. Although 
clinicians usually treat nocturia patients with decreased NBC 
based on their personal experience and use anticholinergic and 
hypnotic agents as well as desmopressin, these treatments have 
not been studied extensively clinically. In the present study, we 
investigated the safety and efficacy of oral desmopressin for the 
treatment of mixed nocturia in patients with both NP and a de-
creased NBC.
 
MATERIALS AND METHODS
Patients aged ≥18 yr with mixed nocturia (≥2 voids/night, noc-
turnal polyuria index [NPi] >33% and NBCi >1) were enrolled in 
this open label, prospective, seven-center study. The formula 
for calculating NPi is simply nocturnal urine volume (NUV) di-
vided by 24-hr urine volume, and NBCi, more complicated for-
mula that addresses voids at night in patients with decreased 
NBC, is defined as the difference between the predicted num-
ber of nightly voids (PNV) and the actual number of nightly voids 
(ANV). PNV is derived by calculating (NUV/MVV) and subtract-
ing 1 (17). The following exclusion criteria were used: nocturia 
due to other defined causes of increased urinary frequency, pri-
mary polydipsia (>40 mL/kg/24 h), neurogenic bladder dysfunc-
tion, urge incontinence, continued post-voiding residual urine 
>150 mL, serum sodium levels <135 mM/L, uncontrolled hy-
pertension, congestive heart failure, use of diuretics, and actual 
or planned pregnancy. The study was performed in accordance 
with the International Conference on Harmonization Good Clin-
ical Practice guidelines, and the principles of the Declaration of 
Helsinki. The study protocol received ethical committee approv-
al at each study site and written informed consent was obtained 
from all patients before recruitment into the study.
  The study included the following periods: screening (1-week), 
dose titration (1-3 weeks), and treatment (4 weeks) (Fig. 1). The 
patients that fulfilled the primary inclusion criteria entered the 
dose titration phase. During an open-label dose-titration period 
of up to 3 weeks, the patients’ optimum oral desmopressin dose 
(0.1, 0.2, or 0.4 mg) was determined as the dose that decreased 
the number of nocturnal voids by ≥50% or decreased NUV by 
≥20% without hyponatremia. If the patients did not meet the 
above criteria during the dose titration period, they received the 
maximum tolerable dose instead of the optimum dose. In addi-
tion, if the patients complained the adverse effects in spite of 
good responses to desmopressin during the dose titration peri-
od, they received the just lower dose instead of the optimum 
dose. Then, eligible patients were treated with the determined 
optimum desmopressin dose for 4 weeks. All patients kept 3-day 
frequency-volume charts (FVC), recorded bedtime and sleep 
disruption, and answered a sleep questionnaire at baseline and 
after treatment. The sleep questionnaire included items about 
the duration of sleep until the first nocturnal void, the frequen-
cy of >5 hr of undisturbed sleep, and the patient’s overall impres-
sion about his/her quality of sleep expressed as feeling fresh in 
the morning or feeling tired in the morning. Clinical and labo-
ratory assessments including body weight, blood and urine anal-
ysis, serum sodium monitoring, and adverse event reports were 
recorded at baseline and after 4 weeks of treatment. The patients 
with serum sodium levels <125 mM/L, symptomatic hypona-
tremia, or intolerable adverse effects were withdrawn from the 
study.
  The efficacy assessments were based on data from the patients’ 
FVC and answers to the sleep questionnaire after the 4-week 
treatment period. The primary efficacy endpoint was the propor-
tion of patients with a 50% or greater reduction in the mean num-
ber of nocturnal voids compared with baseline levels after the 
4-week treatment phase. Secondary endpoints included chang-
es in the mean number of nocturnal voids, changes in the mean 
duration of the period from bedtime to the first nocturnal void 
(first sleep interval), and the proportion of patients that felt they 
Screening/baseline
: Nocturia  ≥2 void/night & NBCi >1 & NPi >33%
Determined dose Desmopressin treatment (4 weeks) 
Completed study & data analysis
Dose titration 
: 0.1 → 0.2 → 0.4 mg 1 week each dose level
: number of nocturia decreased by ≥50% or NUV decreased by ≥20% 
without hyponatramia
Fig. 1. The study design and treatment schedule.
NBCi, nocturnal bladder capacity index; NPi, nocturnal polyuria index; NUV, nocturnal 
urine volume.Lee HW, et al.  •  Desmopressin in Mixed Nocturia
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had a good sleep experience. The safety of oral desmopressin 
was evaluated based on the collected adverse events, body weight 
gain, and laboratory data with an emphasis on serum sodium 
levels. The significance of the results obtained was tested with a 
paired t-test or Wilcoxon’s Signed Rank test according to the nor-
mality of the data. Binary variables such as the quality of sleep 
were analyzed using Generalized Estimating Equations (GEE) 
(P value <0.001). A P value of <0.05 was considered statistically 
significant and the statistical software package SPSS version 
17.0 was used for data management and analysis.
Ethnics statement 
The study was performed in accordance with the International 
Conference on Harmonization Good Clinical Practice guidelines, 
and the principles of the Declaration of Helsinki. The study pro-
tocol, patient information and informed consent forms were 
reviewed and approved by independent review board at each 
study and all patients were informed of the nature and purpose 
of the study (IRB No. 2004-04-05 at Samsung Medical Center). 
Desmopressin was supplied by Ferring Korea Inc. in 2005. This 
study was registered as a clinical tral: ClinicalTrials.gov ID: 
NCT00902655.
 
RESULTS
Among 103 patients enrolled in the dose-titration phase, 9 (8.7%) 
withdrew due to informed consent withdrawal (n=3) and pro-
tocol violation (n=6) during the dose-titration period (Fig. 2). A 
total of 94 patients received the optimal desmopressin dose, and 
90 (95.7%) patients completed the study. Four patients withdrew 
due to neck stiffness (n=1) or loss to follow-up (n=3). The study 
population included 79 men (84%) and 15 women (16%) with a 
median age of 64.2 yr (39–86 yr); their baseline characteristics 
are summarized in Table 1.
  The efficacy analysis included 94 patients that received at 
least one dose of the study drug during the dose-titration peri-
od, had baseline data before the study, and at least one post-
baseline efficacy measurement. During the 4 weeks of active 
treatment, 44% (n=41) of patients received 0.1 mg oral desmo-
pressin, 33% (n=31) received 0.2 mg of desmopressin, and 23% 
(n=22) received 0.4 mg of desmopressin. Overall patient com-
pliance was high; 84 (89.7%) patients took ≥80% of the prescribed 
medication during the treatment period.
  The mean number of nocturnal voids/night was reduced in 
at least 50% compared with baseline levels. In 72% of the patients 
(n=68) (95% CI, 0.63-0.81) (P<0.001), the mean number of noc-
turnal voids decreased significantly from 3.20 to 1.34 after the 
4-week treatment with oral desmopressin (Table 1). Further-
more, the total number of voids/24 hr decreased significantly 
after treatment (11.18 vs 9.15, P<0.001); however, the number 
of mean daytime voids before and after treatment was not sig-
nificantly different (7.97 vs 7.82, P=0.38). Moreover, the factors 
associated with nocturnal urine production including the mean 
NUV, NPi, and nocturnal diuresis all decreased significantly after 
desmopressin treatment. Oral desmopressin treatment was also 
associated with improved nocturnal bladder capacity as evi-
denced by decreases in both the nocturia index (Ni) and NBCi 
(both P<0.001). The mean duration of sleep until the first noc-
turnal void increased from 118.4±44.1 to 220.3±90.7 min (P< 
0.001) (Fig. 3A), and 17 (18%) patients had more than 5 hr of 
undisturbed initial sleep per night after treatment compared to 
none at baseline (Fig. 3B). The overall impression of patients 
about their quality of sleep was improved quality; the number 
of patients who reported a good night of sleep increased signifi-
cantly from 19.8% to 78.7% after desmopressin treatment for 4 
weeks (P<0.001) (Fig. 3C).
Table 1. The baseline characteristics and comparison of secondary endpoints after 4-week desmopressin treatment (n=94)
Variable (Mean±SD) Baseline Treatment % change     P value
No. of nocturia 3.20±1.01 1.34±0.76 -57.9 <0.001
No. of daytime frequency 7.97±2.52 7.82±2.47 -0.04 0.38
No. of 24-hr frequency 11.18±2.83 9.15±2.72 -17 <0.001
Nocturnal urine volume (mL) 725.2±256.1 409.2±199.2 -41.7 <0.001
Nocturnal diuresis (mL/min) 1.57±0.53 0.92±0.43 -39.9 <0.001
Nocturnal polyuria index  43.49±9.0 29.55±9.8 -31.3 <0.001
Nocturnal index  2.57±0.60 1.57±0.58 -38.9 <0.001
Nocturnal Bladder Capacity index 1.62±0.72 0.73±0.48 -54.9 <0.001
Withdrawals (n=6)
Protocol violation (n=3)
AE; neck stiffness (n=1)
Lost to F/U (n=3)
Completed study
n=90
Patients enrolled
N=103
Dose titration period
n=103
Determined dose treatment
0.1 mg (41), 0.2 mg (31), 0.4 mg (22)
Fig. 2. Disposition of patients. 
AE, adverse event; F/U, follow-up.Lee HW, et al.  •  Desmopressin in Mixed Nocturia
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  No significant serum sodium changes (141.8 to 141.5 mM/L, 
P=0.41) or changes in serum creatine (P=0.85), potassium (P= 
0.68), or body weight (P=0.43) were observed in the safety anal-
ysis compared with baseline. One 74-yr-old man treated with 
0.1 mg desmopressin for 4 weeks showed significant hypona-
tremia (132.4 mM/L), but was asymptomatic. Although adverse 
events occurred in a total of 6 (6.4%) patients treated with a de-
mopressin dose of 0.2 mg, the symptoms were generally mild 
(headache [3], facial edema [1], anorexia [1]). One patient with-
drew from the study because of neck stiffness.
 
DISCUSSION
Nocturia can be a symptom of several medical disorders other 
than lower urinary tract abnormalities, and is also a condition 
in its own right. Therefore, it is important that urologists identify 
the precise type and causes of nocturia to treat it effectively. For 
example, in one study, the type of nocturia was classified into 
three groups based on the voiding diaries and the results of uro-
dynamic study (UDS): Pure NP in which the voided urine vol-
ume during the hours of sleep is more than 35% of the 24-hr urine 
volume, DO defined as existing uninhibited contraction on fill-
ing cystometrogram, and mixed (NP with DO). They reported 
that the proportion of NP, DO and mixed type were 50.0%, 7.9%, 
and 17.1% respectively (18). In general, nocturia can be catego-
rized into three types: NP, decreased NBC, mixed nocturia with 
a combination of NP and decreased NBC, or global polyuria 
which refers to urine overproduction over a 24-hr period (19). 
Pharmacological options that could be considered include the 
cautious use of loop diuretics in the afternoon, anti-muscarin-
ics for decreased NBC, and desmopressin for nocturia caused 
by NP. Because the number of patients with mixed nocturia has 
been underestimated and few results about the effect of desmo-
pressin on mixed nocturia have been reported, we analyzed the 
clinical effects of oral desmopressin on patients with mixed noc-
turia by evaluating the improvements in both NP and NBC.
  The results of our study showed that treatment with desmo-
pressin for 4 weeks resulted in a significant improvement in the 
parameters associated with NP including NUV (41.7% reduc-
tion), NPi (31.3% reduction), and nocturnal diuresis (39.9% re-
duction). NP is believed to be responsible for at least 50–65% of 
nocturia cases (9, 20). The hormone AVP is normally released 
into the circulation following the diurnal pattern linked to the 
wake–sleep cycle, and decreases urine production by promot-
ing osmotic re-absorption of solute-free water in the collecting 
tubules (21). Oral desmopressin, is effective against NP because 
it compensates for loss of circadian rhythm-related ADH secre-
tion and furthermore, it causes slight changes in drinking hab-
its. In one randomized, double-blind, placebo-controlled study 
for men ≥18 yr with verified nocturia and Ni >1, the decrease in 
the mean number of nocturnal voids (from 3.0 to 1.7), mean 
nocturnal diuresis (from 1.5 to 0.9 mL/min), and mean ratio of 
night/24-hr urine volume (23%) were significantly different be-
tween the desmopressin and placebo groups (all P<0.001) (15). 
Rembratt et al. (22) also found in a short-term study that des-
mopressin treatment reduced the mean number of nocturnal 
voids and there was a reduction of ≥20% in nocturnal diuresis in 
58 patients (82%) and of ≥50% in 31 (44%). The effects of des-
mopressin on the NP component of nocturia in patients with 
mixed nocturia in the present study are similar to those report-
ed in previous studies which inclusion criteria were not limited 
to mixed nocturia. 
  However, the use of desmopressin for the treatment of noc-
turia with decreased NBC has not been thoroughly evaluated, 
and a standard treatment protocol aimed at improving the de-
crease in NBC has not been developed to date. Our results sug-
gest that oral desmopressin improves nocturia by increasing 
NBC as well as decreasing NUV, which is reflected by improved 
Ni (38.9% reduction) and NBCi (54.9% reduction). Desmopres-
sin most likely improves NBC as follows. Type E2 neurons in and 
around the micturition center directly regulate the activity of the 
bladder, and type E1 and type I neurons modulate the activity of 
type E2 neurons by excitatory and inhibitory effects (23). Des-
mopressin suppresses bladder activity by inhibiting type E1 neu-
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Fig. 3. The effect of desmopressin on the quality of sleep. (A) The duration of the first sleep period. (B) The proportion of more than 5 hr of undisturbed initial sleep per night. (C) 
The overall patient impression about his/her quality of sleep.
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rons or activating type I neurons. Moreover, ureterovesical flow 
has been demonstrated to trigger local and general detrusor ac-
tivity in an unstable bladder by distension of detrusor muscle 
bundles around the ureteric hiatus detrusor activity in a pig mod-
el (24). Based on these findings, desmopressin treatment would 
improve the decreased NBC seen in mixed nocturia patients by 
suppressing detrusor activity and inhibiting neuron-associated 
bladder contraction and the ureterovesical flow rate during sleep.
  The mean duration of the time until the first nocturnal void in 
patients with mixed nocturia was prolonged by desmopressin 
and the patients’ overall impression about their quality of sleep 
improved due to a decrease in the frequency of nocturnal voids 
in the present study. Similarly, Van Kerrebroeck et al. showed 
that the duration of the first sleep period was prolonged by 108 
min (placebo group: 41 min,  P<0.001) and an average of >5 hr 
of unbroken first sleep period per night was experienced by 27% 
of desmopressin-treated patients (placebo group: 9%), result-
ing in a highly significant between-group difference (25). These 
authors reported that two questions concerning the quality of 
sleep and tiredness favored desmopressin over the placebo (P= 
0.02). Among the physiological theories associated with noctur-
nal urine output, sleep is one of the most important factors. El-
derly people with frequent awakenings have a larger part of their 
24-hr urine output at night than those with fewer awakenings 
(26). The ability to sleep without waking is more indicative of 
quality sleep than interrupted longer periods of total sleep time 
during the night. It seems that not only spontaneous sleep, but 
also less fragmented sleep with undisturbed sleep duration, and 
deep stages of sleep with a decreased nocturnal voiding frequen-
cy improve after desmopressin treatment as a result of the effects 
of endogenous in vivo ADH secretion on NU. However, in an-
other study to investigate the effects of long-term oral desmo-
pressin on baseline ADH secretion in elderly patients with noc-
turia, administration of desmopressin for 1 yr in elderly patients 
did not affect baseline ADH secretion in spite of significantly 
decreasing nocturnal urine output and the number of nocturia 
episodes (P<0.01) (27). The practical importance of the increase 
in endogenous ADH with regard to the treatment of NP requires 
further investigation. 
  Finally, the safety analysis of desmopressin in the present 
study confirmed that adverse events associated with treatment 
are infrequent and usually mild. Significant hyponatremia oc-
curred in only one case, and this particular patient was asymp-
tomatic. In addition, other side effects such as body weight gain 
and electrolyte imbalance including sodium abnormalities and 
decreased renal function did not occur. In a meta-analysis of 
the risk of hyponatremia in older adults using desmopressin for 
treatment of nocturia, hyponatremia was found to be a relative-
ly common adverse event with a frequency of 7.6% (28). How-
ever, other studies have suggested that desmopressin has an-
tidiuretic activity for one night or less; a daytime pause in treat-
ment may therefore be sufficient to maintain water and electro-
lyte balance (29, 30). In addition, at least a 10-fold higher-than-
recommended dose did not cause changes in the serum sodi-
um concentration. 
  In conclusion, oral desmopressin treatment results in a signif-
icant improvement in the number of mixed nocturia episodes 
by reducing NUV and increasing NBC. This drug improves the 
quality of sleep by prolonging the period of sleep until the first 
void, and is shown to have an acceptable safety profile. 
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